Elisabetta Bonzano MD, PhD
@elisabettabonzano.bsky.social
240 followers 27 following 100 posts
Radiation Oncologist, MD, PhD Fondazione IRCCS Policlinico San Matteo @UniPv - MIUR Qualified Associate Professor - PhD in Experimental Medicine
Posts Media Videos Starter Packs
elisabettabonzano.bsky.social
📌OncoAlert AF #ESMO25
@oncoalert.bsky.social
See you in Berlin 🇩🇪
oncoalert.bsky.social
See you in Berlin for #ESMO25!
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .

We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
elisabettabonzano.bsky.social
📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

🔗nejm.org/doi/full/10.10…

👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1)

@oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc
elisabettabonzano.bsky.social
📌 Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?
✨Prof @icromeattini.bsky.social
👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc
elisabettabonzano.bsky.social
📌 NRG-BR003: A randomized phase Ill trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative
TNBC.
✨Vicente Valero #ASCO25
@oncoalert.bsky.social #OncoAlertAF
elisabettabonzano.bsky.social
📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer.
✨Erica L. Mayer, MD, MPH, FASCO
✔️Rapid Oral Abstract Session
Breast Cancer-Local/Regional/ Adjuvant
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3
elisabettabonzano.bsky.social
📌 Highlights of the Day II
👉🏻Breast Cancer-Metastatic
✨@maryam_lustberg 👏🏻
🟩 Key takeaways HR+ MBC
🟦 Key takeaways in HER2 positive MBC
🟨 Key Takeaways Metastatic TNBC
@oncoalert.bsky.social #OncoAlertAF #ASCO25
elisabettabonzano.bsky.social
📌 Do We "Node" What to Do About the Axilla❓
Great discussion👏🏻
✨Mediget Teshome, MD, FACS, MPH
@oncoalert.bsky.social #OncoAlertAF #ASCO25
elisabettabonzano.bsky.social
📌 LBA Session❗️
✨DESTINY-Breast09 results ✅
Stunning presentation ✨ @stolaney1.bsky.social 👏🏻

👉🏻 Median PFS:
🔸T-DXd + P: 40.7 mo
🔸THP: 26.9 mo
HR 0.56, p<0.001
👉🏻ORR 85.1%

@oncoalert.bsky.social #OncoAlertAF #ASCO25
Reposted by Elisabetta Bonzano MD, PhD
oncoalert.bsky.social
The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@elisaagostinetto.bsky.social

@erikahamilton9.bsky.social

@drsgraff.bsky.social

@elisabettabonzano.bsky.social
elisabettabonzano.bsky.social
📌Great discussant #ESTRO25

prof @icromeattini.bsky.social 👏🏻👏🏻

✨ Late-Breaking Papers ✨

👉🏻10y FAST-Forward randomised trial
👉🏻 DBCG Skagen trial 1
@oncoalert.bsky.social
Reposted by Elisabetta Bonzano MD, PhD
oncoalert.bsky.social
A Great Presentation by Dr. Hope Rugo 🇺🇸 on Advanced Triple Negative #BreastCancer 🚨 vimeo.com/1077243852?s...

Get caught up on the TOP trials and those that impacted Clinical Practice in less than 2⃣0⃣min

You Can find ALL video here, Free & On Demand👇 oncoalert360.com/oncoalert128...
elisabettabonzano.bsky.social
📌Proud to share our latest review: “Current Treatment Paradigms for Advanced Melanoma with Brain Metastases” 🧠

mdpi.com/1422-0067/26/8…

👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies.
@oncoalert.bsky.soci
a#OncoAlertAFAF
elisabettabonzano.bsky.social
The @oncoalert.bsky.social 🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/l_jcTe69cCs
elisabettabonzano.bsky.social
📌 Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
@oncoalert.bsky.social #OncoAlertAF

thegreenjournal.com/article/S0167-…
elisabettabonzano.bsky.social
📌 Selective Elimination of Breast Surgery for Invasive Breast Cancer
A Nonrandomized Clinical Trial

jamanetwork.com/journals/jam...
@oncoalert.bsky.social
elisabettabonzano.bsky.social
📌 Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer

jamanetwork.com/journals/jam...

@oncoalert.bsky.social
elisabettabonzano.bsky.social
📌 Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism

molecularcancer.biomedcentral.com/articles/10.11…
@oncoalert.bsky.soci
al
elisabettabonzano.bsky.social
📌 Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer
👉🏻 addressing lifestyle factors to improve patient outcomes and quality of life 🚭

ro-journal.biomedcentral.com/articles/10.11…

@oncoalert.bsky.social
Reposted by Elisabetta Bonzano MD, PhD
vjoncology.bsky.social
🚨New #VJOncoAlertJournalClub! with @oncoalert.bsky.social 🗞️

Breaking down the latest in #oncology – every week!

Join Misty Shields as she shares the latest advances in #SCLC, including the game-changing #ADRIATIC trial, DLL3-targeting therapies & more

www.vjoncology.com/video/ayudqc...
Top Advances in SCLC
In this latest episode of the VJOncoAlert Journal Club, Misty Shields, MD, PhD, Indiana University Simon Comprehensive Cancer Center, Indianapolis,...
tinyurl.com
elisabettabonzano.bsky.social
📌 Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation

sciencedirect.com/science/articl…
@oncoalert.bsky.soci
a#OncoAlertAFAF